FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2763088988> ?p ?o ?g. }

• W2763088988 endingPage "2103" @default.
• W2763088988 startingPage "2097" @default.
• W2763088988 abstract "The standard CHOP therapy for peripheral T-cell lymphoma has resulted in unsatisfactory outcomes and it is still not clear what is the optimal front-line therapy. We conducted a multicenter phase II study of dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone (EPOCH) for untreated peripheral T-cell lymphoma patients. In this prospective study, 41 patients were treated with dose-adjusted-EPOCH as initial therapy: peripheral T-cell lymphoma-not otherwise specified, n=21; angioimmunoblastic T-cell lymphoma, n=17; anaplastic lymphoma kinase-positive anaplastic large cell lymphoma, n=2; and anaplastic lymphoma kinase-negative anaplastic large cell lymphoma, n=1. Median patient age was 64 years (range: 32–79 years). According to the International Prognostic Index criteria, 51.2% were at high-intermediate or high risk. The overall response and complete response rates were 78.0% [95% confidence interval (CI): 62.4–89.4%] and 61.0% (95%CI: 44.5–75.8%), respectively. At the median follow up of 24.0 months, the 2-year progression-free survival and overall survival were 53.3% (95%CI: 36.4–67.5%) and 73.2% (95%CI: 56.8–84.1%), respectively. The younger patients (≤ 60 years old) had a high response rate (overall response 94.1% and complete response 70.6%) and survival rate (progression-free survival 62.5% and overall survival 82.4%). The most common grade ≥ 3 adverse events were neutropenia (74.5%), anemia (40.8%), thrombocytopenia (22.0%), and febrile neutropenia (9.0%). Dose-adjusted-EPOCH had a high response rate with a tolerable toxicity profile. Our results indicate that dose-adjusted-EPOCH is a reasonable first-line approach for peripheral T-cell lymphoma patients and may improve outcomes." @default.
• W2763088988 created "2017-10-20" @default.
• W2763088988 creator A5001399725 @default.
• W2763088988 creator A5007888883 @default.
• W2763088988 creator A5022793660 @default.
• W2763088988 creator A5025889209 @default.
• W2763088988 creator A5032293640 @default.
• W2763088988 creator A5036324396 @default.
• W2763088988 creator A5041678137 @default.
• W2763088988 creator A5044860982 @default.
• W2763088988 creator A5050633412 @default.
• W2763088988 creator A5050748706 @default.
• W2763088988 creator A5051924591 @default.
• W2763088988 creator A5053906265 @default.
• W2763088988 creator A5061841627 @default.
• W2763088988 creator A5062419119 @default.
• W2763088988 creator A5062713575 @default.
• W2763088988 creator A5064820220 @default.
• W2763088988 creator A5066277266 @default.
• W2763088988 creator A5074447395 @default.
• W2763088988 date "2017-09-29" @default.
• W2763088988 modified "2023-10-14" @default.
• W2763088988 title "Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707" @default.
• W2763088988 cites W1776168062 @default.
• W2763088988 cites W1853538644 @default.
• W2763088988 cites W1862918409 @default.
• W2763088988 cites W1912693401 @default.
• W2763088988 cites W2001196047 @default.
• W2763088988 cites W2024463580 @default.
• W2763088988 cites W2030087686 @default.
• W2763088988 cites W2050529097 @default.
• W2763088988 cites W2060320162 @default.
• W2763088988 cites W2061368752 @default.
• W2763088988 cites W2074643584 @default.
• W2763088988 cites W2088191368 @default.
• W2763088988 cites W2098666639 @default.
• W2763088988 cites W2125847997 @default.
• W2763088988 cites W2126232974 @default.
• W2763088988 cites W2130410326 @default.
• W2763088988 cites W2131809889 @default.
• W2763088988 cites W2133869962 @default.
• W2763088988 cites W2145164152 @default.
• W2763088988 cites W2149005508 @default.
• W2763088988 cites W2160217770 @default.
• W2763088988 cites W2162389158 @default.
• W2763088988 cites W2163510906 @default.
• W2763088988 cites W2245825568 @default.
• W2763088988 cites W2416844197 @default.
• W2763088988 doi "https://doi.org/10.3324/haematol.2017.167742" @default.
• W2763088988 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5709109" @default.
• W2763088988 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28971899" @default.
• W2763088988 hasPublicationYear "2017" @default.
• W2763088988 type Work @default.
• W2763088988 sameAs 2763088988 @default.
• W2763088988 citedByCount "28" @default.
• W2763088988 countsByYear W27630889882018 @default.
• W2763088988 countsByYear W27630889882019 @default.
• W2763088988 countsByYear W27630889882020 @default.
• W2763088988 countsByYear W27630889882021 @default.
• W2763088988 countsByYear W27630889882022 @default.
• W2763088988 countsByYear W27630889882023 @default.
• W2763088988 crossrefType "journal-article" @default.
• W2763088988 hasAuthorship W2763088988A5001399725 @default.
• W2763088988 hasAuthorship W2763088988A5007888883 @default.
• W2763088988 hasAuthorship W2763088988A5022793660 @default.
• W2763088988 hasAuthorship W2763088988A5025889209 @default.
• W2763088988 hasAuthorship W2763088988A5032293640 @default.
• W2763088988 hasAuthorship W2763088988A5036324396 @default.
• W2763088988 hasAuthorship W2763088988A5041678137 @default.
• W2763088988 hasAuthorship W2763088988A5044860982 @default.
• W2763088988 hasAuthorship W2763088988A5050633412 @default.
• W2763088988 hasAuthorship W2763088988A5050748706 @default.
• W2763088988 hasAuthorship W2763088988A5051924591 @default.
• W2763088988 hasAuthorship W2763088988A5053906265 @default.
• W2763088988 hasAuthorship W2763088988A5061841627 @default.
• W2763088988 hasAuthorship W2763088988A5062419119 @default.
• W2763088988 hasAuthorship W2763088988A5062713575 @default.
• W2763088988 hasAuthorship W2763088988A5064820220 @default.
• W2763088988 hasAuthorship W2763088988A5066277266 @default.
• W2763088988 hasAuthorship W2763088988A5074447395 @default.
• W2763088988 hasBestOaLocation W27630889881 @default.
• W2763088988 hasConcept C121332964 @default.
• W2763088988 hasConcept C126322002 @default.
• W2763088988 hasConcept C1276947 @default.
• W2763088988 hasConcept C141071460 @default.
• W2763088988 hasConcept C143998085 @default.
• W2763088988 hasConcept C150846664 @default.
• W2763088988 hasConcept C2776694085 @default.
• W2763088988 hasConcept C2776755627 @default.
• W2763088988 hasConcept C2777063308 @default.
• W2763088988 hasConcept C2777872185 @default.
• W2763088988 hasConcept C2778119113 @default.
• W2763088988 hasConcept C2778476033 @default.
• W2763088988 hasConcept C2779338263 @default.
• W2763088988 hasConcept C2779429289 @default.
• W2763088988 hasConcept C2779725641 @default.
• W2763088988 hasConcept C2780317896 @default.
• W2763088988 hasConcept C71924100 @default.

• next